Tactile Systems Technology (NASDAQ:TCMD) Shares Climb 12.9% – Should You Buy?

Tactile Systems Technology, Inc. (NASDAQ:TCMD)’s stock price rose 12.9% during mid-day trading on Wednesday. The stock traded as high as $27.25 and last traded at $27.9810. Approximately 68,452 shares were traded during mid-day trading, a decline of 77% from the average daily volume of 300,885 shares. The stock had previously closed at $24.78.

Trending Headlines about Tactile Systems Technology

Here are the key news stories impacting Tactile Systems Technology this week:

• Positive Sentiment: TCMD moved above its 20-day moving average after finding support, a technical signal that may indicate improving short-term momentum. Article: TCMD overtakes 20-day moving average
• Positive Sentiment: Analyst earnings-estimate revisions are trending positively, and average price targets suggest substantial upside, though price targets are not reliable predictors on their own. Article: Analyst targets and estimate revisions
• Positive Sentiment: Third-quarter adjusted earnings were $0.31 per share, above the $0.28 consensus. Lymphedema revenue rose 13% year over year to $81.8 million, and technology improvements cut medical-record review times by about 50%. Article: Three investor takeaways
• Neutral Sentiment: Full-year 2026 revenue guidance of $360 million–$366 million is broadly in line with the $362.5 million consensus. BTIG lowered its price target to $31 from $35 but retained a Buy rating. Article: BTIG rating and price target
• Negative Sentiment: Quarterly revenue of $91.86 million narrowly missed estimates, while earnings per share declined from $0.36 a year earlier. Higher sales and administrative expenses weighed on operating income; the airway-clearance business also shrank, with AffloVest inventory a further concern. Article: Spending outpaces sales

Analysts Set New Price Targets

TCMD has been the topic of a number of recent analyst reports. Weiss Ratings cut Tactile Systems Technology from a “hold (c+)” rating to a “hold (c)” rating in a report on Tuesday. BTIG Research lowered their price target on Tactile Systems Technology from $35.00 to $31.00 and set a “buy” rating for the company in a research note on Tuesday. Finally, Wall Street Zen upgraded shares of Tactile Systems Technology from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Four investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $36.80.

Tactile Systems Technology Price Performance

The stock has a market cap of $634.52 million, a P/E ratio of 27.45 and a beta of 0.95. The stock’s 50 day simple moving average is $22.75 and its two-hundred day simple moving average is $25.88.

Tactile Systems Technology (NASDAQ:TCMD) last posted its quarterly earnings data on Monday, November 2nd. The company reported $0.31 EPS for the quarter, beating the consensus estimate of $0.28 by $0.03. The business had revenue of $91.86 million for the quarter, compared to analysts’ expectations of $91.99 million. Tactile Systems Technology had a net margin of 6.68% and a return on equity of 10.82%. As a group, analysts forecast that Tactile Systems Technology, Inc. will post 1.10 earnings per share for the current fiscal year.

Insider Buying and Selling at Tactile Systems Technology

In other news, CEO Sheri Dodd sold 10,978 shares of Tactile Systems Technology stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $29.44, for a total value of $323,192.32. Following the sale, the chief executive officer directly owned 232,907 shares in the company, valued at $6,856,782.08. This trade represents a 4.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Tactile Systems Technology

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Allspring Global Investments Holdings LLC lifted its holdings in Tactile Systems Technology by 4.1% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 19,071 shares of the company’s stock valued at $425,000 after purchasing an additional 749 shares during the last quarter. State of Wyoming increased its holdings in shares of Tactile Systems Technology by 68.1% in the third quarter. State of Wyoming now owns 18,941 shares of the company’s stock valued at $422,000 after purchasing an additional 7,670 shares during the last quarter. Inspire Investing LLC acquired a new position in shares of Tactile Systems Technology in the third quarter valued at $2,456,000. Pinnacle Associates Ltd. increased its holdings in shares of Tactile Systems Technology by 0.3% in the third quarter. Pinnacle Associates Ltd. now owns 327,967 shares of the company’s stock valued at $7,310,000 after purchasing an additional 850 shares during the last quarter. Finally, State of Alaska Department of Revenue raised its position in shares of Tactile Systems Technology by 18.9% in the third quarter. State of Alaska Department of Revenue now owns 7,113 shares of the company’s stock valued at $158,000 after purchasing an additional 1,132 shares during the period. 83.43% of the stock is owned by institutional investors.

Tactile Systems Technology Company Profile

Tactile Systems Technology, doing business as Tactile Medical, develops and provides medical devices and services for people with chronic swelling and related conditions. The company focuses primarily on lymphedema and chronic venous insufficiency, conditions that can cause persistent fluid buildup in the limbs and trunk.

Its principal products include advanced pneumatic compression devices, such as the Flexitouch Plus system for the treatment of lymphedema and the Entre Plus system for home treatment of lymphedema and chronic venous insufficiency.